WO2011090333A3 - 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물 - Google Patents

클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물 Download PDF

Info

Publication number
WO2011090333A3
WO2011090333A3 PCT/KR2011/000416 KR2011000416W WO2011090333A3 WO 2011090333 A3 WO2011090333 A3 WO 2011090333A3 KR 2011000416 W KR2011000416 W KR 2011000416W WO 2011090333 A3 WO2011090333 A3 WO 2011090333A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
unsaturated fatty
fatty acid
photodynamic therapy
photosensitizers
Prior art date
Application number
PCT/KR2011/000416
Other languages
English (en)
French (fr)
Other versions
WO2011090333A2 (ko
WO2011090333A9 (ko
Inventor
안웅식
바토그토크흐간트므르
김숙희
배수미
문란영
Original Assignee
주식회사 진코스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 진코스 filed Critical 주식회사 진코스
Publication of WO2011090333A2 publication Critical patent/WO2011090333A2/ko
Publication of WO2011090333A3 publication Critical patent/WO2011090333A3/ko
Publication of WO2011090333A9 publication Critical patent/WO2011090333A9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물에 관한 것으로, 클로린 유도체(chlorin derivates)를 도코사헥사에노산(docosahexaenoic acid, DHA) 또는 올레산(oleic acid, OA)과 같은 불포화 지방산에 결합시켜 종양에 대한 선택성이 향상되고 세포 독성이 감소된 클로린 유도체와 불포화 지방산의 접합체를 제공함으로써, 상기 접합체를 광역학적 암 치료에 유용하게 사용할 수 있는 효과가 있다.
PCT/KR2011/000416 2010-01-20 2011-01-20 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물 WO2011090333A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0005312 2010-01-20
KR20100005312 2010-01-20

Publications (3)

Publication Number Publication Date
WO2011090333A2 WO2011090333A2 (ko) 2011-07-28
WO2011090333A3 true WO2011090333A3 (ko) 2011-12-01
WO2011090333A9 WO2011090333A9 (ko) 2012-03-01

Family

ID=44307406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000416 WO2011090333A2 (ko) 2010-01-20 2011-01-20 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101405403B1 (ko)
WO (1) WO2011090333A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101449599B1 (ko) * 2013-06-12 2014-10-13 다이아텍코리아 주식회사 광민감제 탑재 성체 줄기세포 및 그 용도
KR101582252B1 (ko) * 2014-02-17 2016-01-04 대구가톨릭대학교산학협력단 3차원 구형 거대분자를 이용한 광역학 치료용 고농도 광과민제 합성물 및 그 제조방법
KR101665253B1 (ko) 2015-06-19 2016-10-25 순천향대학교 산학협력단 도코사헥사에노산 및 트리아신 씨를 포함하는 것을 특징으로 하는 자궁내막암 치료 및 예방용 조성물
KR101668561B1 (ko) 2015-07-13 2016-10-21 원광대학교산학협력단 녹색형광단백질을 발현하는 유전자 및 로즈 벵갈을 이용한 암 질환의 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
KR101911725B1 (ko) 2017-01-16 2018-12-28 주식회사 코어파마 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
CN116746546A (zh) * 2017-02-10 2023-09-15 施明哲 调节纤维母细胞生长因子受体3活化的组合物及方法
KR102266865B1 (ko) * 2020-01-10 2021-06-18 가톨릭대학교 산학협력단 지방산을 유효성분으로 포함하는 수용성 광감작제 결합체 및 이의 제조방법
KR102523940B1 (ko) * 2020-05-21 2023-04-20 가톨릭대학교 산학협력단 광감각제가 접합된 장내분비세포 표적 고분자 물질 및 이의 대사질환 개선을 위한 의학적 용도
CN112451680B (zh) * 2020-11-24 2022-07-19 吉林化工学院 一种具有协同诱导光动力治疗和铁死亡的ros敏感性纳米试剂及其制备方法
CN113018267B (zh) * 2021-03-22 2022-07-01 沈阳药科大学 不饱和脂肪酸-光敏剂共组装纳米粒及其构建方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080253960A1 (en) * 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
US20090149525A1 (en) * 2004-11-16 2009-06-11 Universidade De Coimbra Novel derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy
WO2009073984A1 (en) * 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080253960A1 (en) * 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
US20090149525A1 (en) * 2004-11-16 2009-06-11 Universidade De Coimbra Novel derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy
WO2009073984A1 (en) * 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles

Also Published As

Publication number Publication date
KR101405403B1 (ko) 2014-06-11
KR20110085935A (ko) 2011-07-27
WO2011090333A2 (ko) 2011-07-28
WO2011090333A9 (ko) 2012-03-01

Similar Documents

Publication Publication Date Title
WO2011090333A3 (ko) 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
IN2012MN02591A (ko)
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
MX2012007981A (es) Derivados de fumarato de acido graso y sus usos.
MX344316B (es) Nuevos compuestos nitrosos como donadores de nitroxilo y metodos de uso de los mismos.
TN2014000540A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
IN2014MN02069A (ko)
EP2490684A4 (en) METHODS AND NUTRITION FORMULATIONS FOR INCREASING EFFICIENCY AND MINIMIZING THE SIDE EFFECTS OF CANCER TREATMENT
MX2014004861A (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
EP4403216A3 (en) Substituted tricyclic compounds as fgfr inhibitors
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
IN2014MN00987A (ko)
NZ596228A (en) Compositions and methods for the treatment of inflammation
EP3760638A3 (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
WO2009095261A3 (en) Vaccine compositions
NZ700399A (en) Boronic acid conjugates of oligonucleotide analogues
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
WO2013116753A8 (en) Fatty acids as anti-inflammatory agents
WO2010151074A3 (ko) 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물
WO2012040331A3 (en) Multistage nanoparticles
WO2010088527A3 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
NZ603261A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
HK1210058A1 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11734882

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 26/09/2012)

122 Ep: pct application non-entry in european phase

Ref document number: 11734882

Country of ref document: EP

Kind code of ref document: A2